ASCO is a renowned scientific conference that brings together oncology professionals and patient advocates from around the world. Dedicated to advancing cancer research and development, over 5,000 abstracts are expected to be presented or published during the upcoming 2024 event. Here we have compiled a summary of potential small molecule candidates for cancer treatment. The information is based on abstracts online from available poster sessions.

Targeted Protein Degradation (TPD) mainly involves the degradation of target proteins through the ubiquitin-proteasome and lysosome systems. There are nearly ten different technological routes within TPD, among which molecular glue and PROTAC are the fastest growing ones.

The most eye-catching event for medicinal chemists in August was the American Chemical Society (ACS) 2023 Annual Meeting in autumn, during which the latest research results announced by pharmaceutical manufacturers touched every nerve of medicinal chemistr

Last week's American Chemical Society (ACS) 2023 Annual Autumn Meeting in San Francisco, USA, was a great source of inspiration for the innovative drug industry.

The American Chemical Society's (ACS) 2023 Annual Meeting was held in San Francisco, USA, from 13 to 17 August, with the theme of Harnessing the Power of Data.

Despite its natural advantages in terms of safety and selectivity, the peptide's Achilles' heel (originally the heel of Achilles, which became his only weakness as it was the only part of his body not immersed in the waters of the River Styx).

Once a Nobel Prize winner, Alnylam was once rejected by pharmaceutical companies and investors because of safety concerns. At this moment, Alnylam's lipid nanoparticle delivery system (LNP) has successfully brought RNA interference therapy from the clinic

In the last two years, after small molecules and antibody drugs, small nucleic acid drugs have also gained attention.

The parent company participated in the 88th China International Pharmaceutical API/ Intermediate/ Packaging/ Equipment Fair (API China) and the 26th China International Pharmaceutical (Industry) Exhibition & Technical Exchange Conference (CHINA-PHARM).

The parent company participated in the SAPA-China Annual Conference.

On February 20, 2023, Astellas ("Astellas") announced that the FDA notified a three-month extension of the PDUFA target date for fezolinetant to May 22, 2023, to allow additional time to complete the review.

Eli Lilly and Company, which seems to be losing the battle for the insulin market - facing the squeeze from Sanofi and Novo Nordisk - has seen its insulin market share slip from 38% in 2000 to 13.14% currently.

The parent company participated in the12th Annual ChemPharma International Summit-Asia CIS-Asia 2023.

The Ubiquitin-proteasome system (UPS) is an important pathway for selective protein degradation.

Antibody-drug conjugates (ADCs) consist of monoclonal antibodies (Antibody) targeting tumor-specific or tumor-associated antigens coupled with different numbers of small molecule toxins (Payload) through a linker, combining the high targeting ability of monoclonal antibodies and the high activity of cytotoxins in tumor tissues. It has the dual advantages of high targeting of monoclonal antibodies and high activity of cytotoxic agents in tumor tissues, and has better efficacy than traditional antibody-based oncology drugs.

We sat down with some of the original team members from Schrödinger and Nimbus Therapeutics who led the tyrosine kinase 2 (TYK2) inhibitor program that resulted in NDI-034858, an oral, selective allosteric inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent Phase 2b results in psoriasis. On December 24, 2022, Takeda entered into an agreement to acquire Nimbus Lakshmi, Inc., a wholly-owned subsidiary of Nimbus Therapeutics, and it’s TK2 inhibitor, NDI-034858, in a $6 billion deal, with $4 billion up front. Here they discuss the challenges they faced and how these were overcome to successfully develop a potential best-in-class medicine – because they had the right vision and mindset to do things very differently.

In this blog, I tell an important part of the scientific adventure story that led to the discovery a novel medicine called deucravacitinib (Sotyktu™). [Disclaimer: I am a full-time employee at Bristol Myers Squibb.

Cancer cells grow and divide out of control, and spread into surrounding tissues, causing genetic changes. Tobacco use, age and family history, human papillomavirus (HPV), overweight and obesity, and alcohol consumption are found be risk factors for cancer

Human immunodeficiency virus 1 (HIV) is a virus that attacks the immune system by destroying CD4+ T cells (a type of white blood cell that fights infection).

Aziridine derivatives are aza-analogs of epoxides. The aziridine functionality is a valuable intermediate in synthetic organic and medicinal chemistry.